Your browser doesn't support javascript.
loading
External validation of pulmonary radiotherapy toxicity models for ultracentral lung tumors.
Chen, Ishita; Wu, Abraham J; Jackson, Andrew; Patel, Purvi; Sun, Lian; Ng, Angela; Iyer, Aditi; Apte, Aditya; Rimner, Andreas; Gomez, Daniel; Deasy, Joseph O; Thor, Maria.
Afiliação
  • Chen I; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Wu AJ; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Jackson A; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NYv.
  • Patel P; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NYv.
  • Sun L; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NYv.
  • Ng A; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NYv.
  • Iyer A; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NYv.
  • Apte A; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NYv.
  • Rimner A; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Gomez D; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
  • Deasy JO; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NYv.
  • Thor M; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NYv.
Clin Transl Radiat Oncol ; 38: 57-61, 2023 Jan.
Article em En | MEDLINE | ID: mdl-36388248
ABSTRACT

Introduction:

Pulmonary toxicity is dose-limiting in stereotactic body radiation therapy (SBRT) for tumors that abut the proximal bronchial tree (PBT), esophagus, or other mediastinal structures. In this work we explored published models of pulmonary toxicity following SBRT for such ultracentral tumors in an independent cohort of patients.

Methods:

The PubMed database was searched for pulmonary toxicity models. Identified models were tested in a cohort of patients with ultracentral lung tumors treated between 2008 and 2017 at one large center (N = 88). This cohort included 60 % primary and 40 % metastatic tumors treated to 45 Gy in 5 fractions (fx), 50 Gy in 5 fx, 60 Gy in 8 fx, or 60 Gy in 15 fx prescribed as 100 % dose to PTV.

Results:

Seven published NTCP models from two studies were identified. The NTCP models utilized PBT max point dose (Dmax), D0.2 cm3, V65, V100, and V130. Within the independent cohort, the ≥ grade 3 toxicity and grade 5 toxicity rates were 18 % and 7-10 %, respectively, and the Dmax models best described pulmonary toxicity. The Dmax to 0.1 cm3 model was better calibrated and had increased steepness compared to the Dmax model. A re-planning study minimizing PBT 0.1 cm3 to below 122 Gy in EQD23 (for a 10 % ≥grade 3 pulmonary toxicity) was demonstrated to be completely feasible in 4/6 patients, and dose to PBT 0.1 cm3 was considerably lowered in all six patients.

Conclusions:

Pulmonary toxicity models were identified from two studies and explored within an independent ultracentral lung tumor cohort. A modified Dmax to 0.1 cm3 PBT model displayed the best performance. This model could be utilized as a starting point for rationally constructed airways constraints in ultracentral patients treated with SBRT or hypofractionation.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Transl Radiat Oncol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Transl Radiat Oncol Ano de publicação: 2023 Tipo de documento: Article